{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:43:22Z","timestamp":1774604602429,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","liver.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.cld.2017.06.003","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T00:00:37Z","timestamp":1501113637000},"page":"697-707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Liver in Oncology"],"prefix":"10.1016","volume":"21","author":[{"given":"Renu","family":"Dhanasekaran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul Y.","family":"Kwo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cld.2017.06.003_bib1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2017.06.003_bib2","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2017.06.003_bib3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1053\/j.gastro.2016.10.010","article-title":"Drug-induced liver injury in patients with preexisting chronic liver disease in drug development: how to identify and manage?","volume":"151","author":"Chalasani","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2017.06.003_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1634\/theoncologist.6-2-162","article-title":"Hepatotoxicity of chemotherapy","volume":"6","author":"King","year":"2001","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.cld.2017.06.003_bib5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/CAD.0b013e328356f5b0","article-title":"Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review","volume":"23","author":"Dixit","year":"2012","journal-title":"Anticancer Drugs"},{"issue":"2","key":"10.1016\/j.cld.2017.06.003_bib6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00007611-198502000-00034","article-title":"Cyclophosphamide-associated hepatotoxicity","volume":"78","author":"Goldberg","year":"1985","journal-title":"South Med J"},{"issue":"2","key":"10.1016\/j.cld.2017.06.003_bib7","first-page":"95","article-title":"Hepatotoxicity secondary to chemotherapy","volume":"2","author":"Grigorian","year":"2014","journal-title":"J\u00a0Clin Transl Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2017.06.003_bib8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archinte.1968.00300060056011","article-title":"Hepatotoxicity of mercaptopurine","volume":"122","author":"Shorey","year":"1968","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1016\/j.cld.2017.06.003_bib9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-111-8-641","article-title":"6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity","volume":"111","author":"Present","year":"1989","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.cld.2017.06.003_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF01300713","article-title":"Sclerosing hepatitis and azathioprine","volume":"31","author":"Barrowman","year":"1986","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.cld.2017.06.003_bib11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.7326\/0003-4819-123-3-199508010-00018","article-title":"Tamoxifen-induced steatohepatitis","volume":"123","author":"Pratt","year":"1995","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.cld.2017.06.003_bib12","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/1097-0142(19841101)54:9<2006::AID-CNCR2820540937>3.0.CO;2-F","article-title":"Hepatotoxicity following vincristine therapy","volume":"54","author":"el Saghir","year":"1984","journal-title":"Cancer"},{"issue":"5 Suppl 10","key":"10.1016\/j.cld.2017.06.003_bib13","first-page":"42","article-title":"A\u00a0summary of vinorelbine (Navelbine) safety data from North American clinical trials","volume":"21","author":"Hohneker","year":"1994","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.cld.2017.06.003_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.seminoncol.2005.11.002","article-title":"Hepatotoxicity of chemotherapy","volume":"33","author":"Floyd","year":"2006","journal-title":"Semin Oncol"},{"issue":"21","key":"10.1016\/j.cld.2017.06.003_bib15","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1200\/JCO.2002.03.123","article-title":"Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction","volume":"20","author":"Raymond","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.cld.2017.06.003_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.critrevonc.2014.11.006","article-title":"Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of randomized clinical trials","volume":"93","author":"Ghatalia","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.cld.2017.06.003_bib17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-2125.2009.03459.x","article-title":"Three cases of severe hepatic impairment caused by erlotinib","volume":"68","author":"Huang","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"16","key":"10.1016\/j.cld.2017.06.003_bib18","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.2165\/10489100-000000000-00000","article-title":"Gefitinib: a review of its use in the treatment of locally advanced\/metastatic non-small cell lung cancer","volume":"69","author":"Sanford","year":"2009","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.cld.2017.06.003_bib19","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cgh.2007.04.014","article-title":"Fulminant hepatic failure secondary to erlotinib","volume":"5","author":"Liu","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2017.06.003_bib20","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.cld.2017.06.003_bib21","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/JCO.2013.50.9448","article-title":"Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial","volume":"31","author":"Azim","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.cld.2017.06.003_bib22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1158\/1078-0432.CCR-15-2044","article-title":"HLA-B*57:01 confers susceptibility to pazopanib-associated liver injury in patients with cancer","volume":"22","author":"Xu","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.cld.2017.06.003_bib23","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2008.20.0931","article-title":"Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301","volume":"27","author":"Miller","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.cld.2017.06.003_bib24","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/annonc\/mdh324","article-title":"Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome\/veno-occlusive disease","volume":"15","author":"Nabhan","year":"2004","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.cld.2017.06.003_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/ncponc1087","article-title":"Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy","volume":"5","author":"Loriot","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.cld.2017.06.003_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.30678","article-title":"Risk of hepatotoxicity in cancer patients Treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data","author":"Wang","year":"2017","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.cld.2017.06.003_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/CMR.0b013e32835c7e68","article-title":"Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma","volume":"23","author":"Bernardo","year":"2013","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1016\/j.cld.2017.06.003_bib28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment","volume":"22","author":"Dalle","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.cld.2017.06.003_bib29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"10.1016\/j.cld.2017.06.003_bib30","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cld.2017.06.003_bib31","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.bbmt.2017.03.008","article-title":"Defibrotide for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome: interim results from a treatment IND study","volume":"23","author":"Richardson","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.cld.2017.06.003_bib32","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/hep.1840110512","article-title":"Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules","volume":"11","author":"Wanless","year":"1990","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2017.06.003_bib33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0034-1375963","article-title":"Drug-induced nodular regenerative hyperplasia","volume":"34","author":"Ghabril","year":"2014","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10.1016\/j.cld.2017.06.003_bib34","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jhep.2013.08.013","article-title":"Non-cirrhotic portal hypertension - diagnosis and management","volume":"60","author":"Khanna","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2017.06.003_bib35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cld.2017.06.003_bib36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/lt.500050113","article-title":"Management of hepatic metastases","volume":"5","author":"Choti","year":"1999","journal-title":"Liver Transpl Surg"},{"issue":"20","key":"10.1016\/j.cld.2017.06.003_bib37","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1002\/cncr.28743","article-title":"Surgical management of noncolorectal cancer liver metastases","volume":"120","author":"Page","year":"2014","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.cld.2017.06.003_bib38","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/annonc\/mdn735","article-title":"Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel","volume":"20","author":"Nordlinger","year":"2009","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.cld.2017.06.003_bib39","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/bjs.9449","article-title":"Systematic review of surgical management of synchronous colorectal liver metastases","volume":"101","author":"Lykoudis","year":"2014","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.cld.2017.06.003_bib40","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.cld.2017.06.003_bib41","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.gassur.2003.11.010","article-title":"Liver transplantation for neuroendocrine tumors","volume":"8","author":"Florman","year":"2004","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"1","key":"10.1016\/j.cld.2017.06.003_bib42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11605-012-2047-7","article-title":"Multivisceral transplantation: expanding indications and improving outcomes","volume":"17","author":"Mangus","year":"2013","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"3","key":"10.1016\/j.cld.2017.06.003_bib43","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/jrr\/rrw008","article-title":"Threshold doses and prediction of visually apparent liver dysfunction after stereotactic body radiation therapy in cirrhotic and normal livers using magnetic resonance imaging","volume":"57","author":"Doi","year":"2016","journal-title":"J\u00a0Radiat Res"},{"issue":"3","key":"10.1016\/j.cld.2017.06.003_bib44","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/hep.26191","article-title":"Prognostic factors and prevention of radioembolization-induced liver disease","volume":"57","author":"Gil-Alzugaray","year":"2013","journal-title":"Hepatology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932611730051X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932611730051X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T20:25:05Z","timestamp":1719347105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108932611730051X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S108932611730051X"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2017.06.003","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Liver in Oncology","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2017.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}